Browse > Article
http://dx.doi.org/10.5483/BMBRep.2020.53.6.060

Angiogenesis and vasculogenic mimicry as therapeutic targets in ovarian cancer  

Lim, Dansaem (Division of Biological Sciences, Sookmyung Women's University)
Do, Yeojin (Division of Biological Sciences, Sookmyung Women's University)
Kwon, Byung Su (Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Biomedical Research Institute, Pusan National University Hospital)
Chang, Woochul (Department of Biology Education, College of Education, Pusan National University)
Lee, Myeong-Sok (Division of Biological Sciences, Sookmyung Women's University)
Kim, Jongmin (Division of Biological Sciences, Sookmyung Women's University)
Cho, Jin Gu (Division of Biological Sciences, Sookmyung Women's University)
Publication Information
BMB Reports / v.53, no.6, 2020 , pp. 291-298 More about this Journal
Abstract
Tumor angiogenesis is an essential process for growth and metastasis of cancer cells as it supplies tumors with oxygen and nutrients. During tumor angiogenesis, many pro-angiogenic factors are secreted by tumor cells to induce their own vascularization via activation of pre-existing host endothelium. However, accumulating evidence suggests that vasculogenic mimicry (VM) is a key alternative mechanism for tumor vascularization when tumors are faced with insufficient supply of oxygen and nutrients. VM is a tumor vascularization mechanism in which tumors create a blood supply system, in contrast to tumor angiogenesis mechanisms that depend on pre-existing host endothelium. VM is closely associated with tumor progression and poor prognosis in many cancers. Therefore, inhibition of VM may be a promising therapeutic strategy and may overcome the limitations of anti-angiogenesis therapy for cancer patients. In this review, we provide an overview of the current anti-angiogenic therapies for ovarian cancer and the current state of knowledge regarding the links between microRNAs and the VM process, with a focus on the mechanism that regulates associated signaling pathways in ovarian cancer. Moreover, we discuss the potential for VM as a therapeutic strategy against ovarian cancer.
Keywords
Angiogenesis; Ovarian cancer; Therapeutic target; Tumor vascularization; Vasculogenic mimicry;
Citations & Related Records
Times Cited By KSCI : 20  (Citation Analysis)
연도 인용수 순위
1 Sestito R, Cianfrocca R, Rosano L et al (2016) Macitentan blocks endothelin-1 receptor activation required for chemoresistant ovarian cancer cell plasticity and metastasis. Life Sci 159, 43-48   DOI
2 Orecchia P, Balza E, Pietra G et al (2019) L19-IL2 Immunocytokine in Combination with the Anti-Syndecan-1 46F2SIP Antibody Format: A New Targeted Treatment Approach in an Ovarian Carcinoma Model. Cancers (Basel) 11, 1232-1250   DOI
3 Kim J (2018) MicroRNAs as critical regulators of the endothelial to mesenchymal transition in vascular biology. BMB Rep 51, 65-72   DOI
4 Hernandez R, Sanchez-Jimenez E, Melguizo C, Prados J and Rama AR (2018) Downregulated microRNAs in the colorectal cancer: diagnostic and therapeutic perspectives. BMB Rep 51, 563-571   DOI
5 Suh N (2018) MicroRNA controls of cellular senescence. BMB Rep 51, 493-499   DOI
6 Kinose Y, Sawada K, Nakamura K and Kimura T (2014) The role of microRNAs in ovarian cancer. Biomed Res Int 2014, 249393   DOI
7 Sun Q, Zou X, Zhang T, Shen J, Yin Y and Xiang J (2014) The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer. Gynecol Oncol 132, 730-738   DOI
8 Salinas-Vera YM, Gallardo-Rincon D, Garcia-Vazquez R et al (2019) HypoxamiRs Profiling Identify miR-745 as a Regulator of the Early Stages of Vasculogenic Mimicry in SKOV3 Ovarian Cancer Cells. Front Oncol 9, 381   DOI
9 Cao L, Wan Q, Li F and Tang CE (2018) MiR-363 inhibits cisplatin chemoresistance of epithelial ovarian cancer by regulating snail-induced epithelial-mesenchymal transition. BMB Rep 51, 456-461   DOI
10 Choi PW and Ng SW (2017) The Functions of MicroRNA-200 Family in Ovarian Cancer: Beyond Epithelial-Mesenchymal Transition. Int J Mol Sci 18, 1207-1226   DOI
11 Shibuya M (2008) Vascular endothelial growth factordependent and -independent regulation of angiogenesis. BMB Rep 41, 278-286   DOI
12 Monk BJ, Minion LE and Coleman RL (2016) Antiangiogenic agents in ovarian cancer: past, present, and future. Ann Oncol 27 Suppl 1, i33-i39   DOI
13 Siegel RL, Miller KD and Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69, 7-34   DOI
14 Sudo T (2012) Molecular-targeted therapies for ovarian cancer: prospects for the future. Int J Clin Oncol 17, 424-429   DOI
15 Hennessy BT, Coleman RL and Markman M (2009) Ovarian cancer. Lancet 374, 1371-1382   DOI
16 Webb PM and Jordan SJ (2017) Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 41, 3-14   DOI
17 Park JA and Kwon YG (2018) Hippo-YAP/TAZ signaling in angiogenesis. BMB Rep 51, 157-162   DOI
18 Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29, 15-18   DOI
19 Ribatti D, Annese T, Ruggieri S, Tamma R and Crivellato E (2019) Limitations of Anti-Angiogenic Treatment of Tumors. Transl Oncol 12, 981-986   DOI
20 Dunleavey JM and Dudley AC (2012) Vascular Mimicry: Concepts and Implications for Anti-Angiogenic Therapy. Curr Angiogenes 1, 133-138   DOI
21 Maniotis AJ, Folberg R, Hess A et al (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol 155, 739-752   DOI
22 Zhang X, Zhang J, Zhou H, Fan G and Li Q (2019) Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry. J Cancer 10, 6327-6340   DOI
23 Chae YC and Kim JH (2018) Cancer stem cell metabolism: target for cancer therapy. BMB Rep 51, 319-326   DOI
24 Sood AK, Fletcher MS, Zahn CM et al (2002) The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Cancer Biol Ther 1, 661-664   DOI
25 Park Y and Kim J (2019) Regulation of IL-6 signaling by miR-125a and let-7e in endothelial cells controls vasculogenic mimicry formation of breast cancer cells. BMB Rep 52, 214-219   DOI
26 Fan YL, Zheng M, Tang YL and Liang XH (2013) A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett 6, 1174-1180   DOI
27 Yu L, Zhu B, Wu S et al (2017) Evaluation of the correlation of vasculogenic mimicry, ALDH1, KiSS-1, and MACC1 in the prediction of metastasis and prognosis in ovarian carcinoma. Diagn Pathol 12, 23   DOI
28 Liang J, Yang B, Cao Q and Wu X (2016) Association of Vasculogenic Mimicry Formation and CD133 Expression with Poor Prognosis in Ovarian Cancer. Gynecol Obstet Invest 81, 529-536   DOI
29 Zhang D, Sun B, Zhao X et al (2014) Twist1 expression induced by sunitinib accelerates tumor cell vasculogenic mimicry by increasing the population of CD133+ cells in triple-negative breast cancer. Mol Cancer 13, 207   DOI
30 Xu Y, Li Q, Li XY, Yang QY, Xu WW and Liu GL (2012) Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis. J Exp Clin Cancer Res 31, 16   DOI
31 Carmeliet P (2005) Angiogenesis in life, disease and medicine. Nature 438, 932-936   DOI
32 Boocock CA, Charnock-Jones DS, Sharkey AM et al (1995) Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87, 506-516   DOI
33 Markowska A, Sajdak S, Markowska J and Huczynski A (2017) Angiogenesis and cancer stem cells: New perspectives on therapy of ovarian cancer. Eur J Med Chem 142, 87-94   DOI
34 Chen Y, Zhang L, Liu WX and Wang K (2018) VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer. Cell Mol Biol Lett 23, 2   DOI
35 Wang JY, Sun T, Zhao XL et al (2008) Functional significance of VEGF-a in human ovarian carcinoma: role in vasculogenic mimicry. Cancer Biol Ther 7, 758-766   DOI
36 Reinthaller A (2016) Antiangiogenic therapies in ovarian cancer. Memo 9, 139-143   DOI
37 Richardson DL (2019) New and Novel Therapies for Gynecologic Cancers. Semin Oncol Nurs 35, 217-219   DOI
38 Cortez AJ, Tudrej P, Kujawa KA and Lisowska KM (2018) Advances in ovarian cancer therapy. Cancer Chemother Pharmacol 81, 17-38   DOI
39 Wedge SR, Kendrew J, Hennequin LF et al (2005) AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 65, 4389-4400   DOI
40 Ledermann JA, Embleton AC, Raja F et al (2016) Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 387, 1066-1074   DOI
41 Raja FA, Griffin CL, Qian W et al (2011) Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer. Br J Cancer 105, 884-889   DOI
42 Pick AM and Nystrom KK (2012) Pazopanib for the treatment of metastatic renal cell carcinoma. Clin Ther 34, 511-520   DOI
43 Yu K, Xiang L, Li S, Wang S, Chen C and Mu H (2019) HIF1alpha promotes prostate cancer progression by increasing ATG5 expression. Anim Cells Syst (Seoul) 23, 326-334   DOI
44 Schoffski P (2012) Pazopanib in the treatment of soft tissue sarcoma. Expert Rev Anticancer Ther 12, 711-723   DOI
45 Cong R, Sun Q, Yang L, Gu H, Zeng Y and Wang B (2009) Effect of Genistein on vasculogenic mimicry formation by human uveal melanoma cells. J Exp Clin Cancer Res 28, 124   DOI
46 Cheng N, Brantley DM, Liu H et al (2002) Blockade of EphA receptor tyrosine kinase activation inhibits vascular endothelial cell growth factor-induced angiogenesis. Mol Cancer Res 1, 2-11   DOI
47 Manandhar S and Lee YM (2018) Emerging role of RUNX3 in the regulation of tumor microenvironment. BMB Rep 51, 174-181   DOI
48 Zimna A and Kurpisz M (2015) Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies. Biomed Res Int 2015, 549412   DOI
49 Zhang S, Zhang D and Sun B (2007) Vasculogenic mimicry: current status and future prospects. Cancer Lett 254, 157-164   DOI
50 Sun B, Zhang D, Zhang S, Zhang W, Guo H and Zhao X (2007) Hypoxia influences vasculogenic mimicry channel formation and tumor invasion-related protein expression in melanoma. Cancer Lett 249, 188-197   DOI
51 Su M, Feng YJ, Yao LQ et al (2008) Plasticity of ovarian cancer cell SKOV3ip and vasculogenic mimicry in vivo. Int J Gynecol Cancer 18, 476-486   DOI
52 Herr F, Baal N, Reisinger K et al (2007) HCG in the regulation of placental angiogenesis. Results of an in vitro study. Placenta 28 Suppl A, S85-93   DOI
53 du Bois A, Kristensen G, Ray-Coquard I et al (2016) Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 17, 78-89   DOI
54 Pignata S, Lorusso D, Scambia G et al (2015) Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial. Lancet Oncol 16, 561-568   DOI
55 du Bois A, Floquet A, Kim JW et al (2014) Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol 32, 3374-3382   DOI
56 Floquet A, Vergote I, Colombo N et al (2015) Progressionfree survival by local investigator versus independent central review: comparative analysis of the AGO-OVAR16 Trial. Gynecol Oncol 136, 37-42   DOI
57 Muller CY and Cole LA (2009) The quagmire of hCG and hCG testing in gynecologic oncology. Gynecol Oncol 112, 663-672   DOI
58 Su M, Wei W, Xu X et al (2011) Role of hCG in vasculogenic mimicry in OVCAR-3 ovarian cancer cell line. Int J Gynecol Cancer 21, 1366-1374   DOI
59 Awasthi N and Schwarz RE (2015) Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther 8, 3691-3701   DOI
60 Hughes G, Toellner H, Morris H, Leonard C and Chaudhuri N (2016) Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis. J Clin Med 5, 78-89   DOI
61 Monk BJ, Poveda A, Vergote I et al (2014) Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 15, 799-808   DOI
62 van Beijnum JR, Nowak-Sliwinska P, Huijbers EJ, Thijssen VL and Griffioen AW (2015) The great escape; the hallmarks of resistance to antiangiogenic therapy. Pharmacol Rev 67, 441-461   DOI
63 Sood AK, Seftor EA, Fletcher MS et al (2001) Molecular determinants of ovarian cancer plasticity. Am J Pathol 158, 1279-1288   DOI
64 Vartanian AA, Burova OS, Stepanova EV and Baryshnikov AY (2007) The involvement of apoptosis in melanoma vasculogenic mimicry. Melanoma Res 17, 1-8   DOI
65 Gao S, Fan C, Huang H, Zhu C, Su M and Zhang Y (2016) Effects of HCG on human epithelial ovarian cancer vasculogenic mimicry formation in vivo. Oncol Lett 12, 459-466   DOI
66 Qiao L, Gu Q, Dai Y et al (2008) XIAP-associated factor 1 (XAF1) suppresses angiogenesis in mouse endothelial cells. Tumour Biol 29, 122-129   DOI
67 Zhu LM, Shi DM, Dai Q et al (2014) Tumor suppressor XAF1 induces apoptosis, inhibits angiogenesis and inhibits tumor growth in hepatocellular carcinoma. Oncotarget 5, 5403-5415   DOI
68 Wang Y, Liu P, Wang X and Mao H (2017) Role of Xlinked inhibitor of apoptosisassociated factor1 in vasculogenic mimicry in ovarian cancer. Mol Med Rep 16, 325-330   DOI
69 Dejana E (2010) The role of wnt signaling in physiological and pathological angiogenesis. Circ Res 107, 943-952   DOI
70 Kim NH, Lee Y and Yook JI (2018) Dishevelling Wnt and Hippo. BMB Rep 51, 425-426   DOI
71 Qi H, Sun B, Zhao X et al (2014) Wnt5a promotes vasculogenic mimicry and epithelial-mesenchymal transition via protein kinase Calpha in epithelial ovarian cancer. Oncol Rep 32, 771-779   DOI
72 Czekierdowski A, Czekierdowska S, Stachowicz N, Lozinski T and Gurynowicz G (2017) Mig-7 expression and vasculogenic mimicry in malignant ovarian tumors. Ginekol Pol 88, 552-561   DOI
73 Jo HN, Kang H, Lee A et al (2017) Endothelial miR-26a regulates VEGF-Nogo-B receptor-mediated angiogenesis. BMB Rep 50, 384-389   DOI
74 Carmeliet P and Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307   DOI
75 Rabbani SA and Mazar AP (2001) The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 10, 393-415, x   DOI
76 Tang J, Wang J, Fan L et al (2016) cRGD inhibits vasculogenic mimicry formation by down-regulating uPA expression and reducing EMT in ovarian cancer. Oncotarget 7, 24050-24062   DOI
77 Hendrix MJ, Seftor EA, Meltzer PS et al (2001) Expression and functional significance of VE-cadherin in aggressive human melanoma cells: role in vasculogenic mimicry. Proc Natl Acad Sci U S A 98, 8018-8023   DOI
78 Du J, Sun B, Zhao X et al (2014) Hypoxia promotes vasculogenic mimicry formation by inducing epithelialmesenchymal transition in ovarian carcinoma. Gynecol Oncol 133, 575-583   DOI
79 Liu W, Lv C, Zhang B, Zhou Q and Cao Z (2017) MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression. RNA 23, 1019-1027   DOI
80 Lapeyre-Prost A, Terme M, Pernot S et al (2017) Immunomodulatory Activity of VEGF in Cancer. Int Rev Cell Mol Biol 330, 295-342   DOI
81 Jeong MS, Bae JS and Jin HK (2019) Vascular endothelial growth factor improves the therapeutic effects of cyclodextrin in Niemann-Pick type C mice. Anim Cells Syst (Seoul) 23, 346-354   DOI
82 Mei J, Gao Y, Zhang L et al (2008) VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro. Exp Oncol 30, 29-34
83 Qin L, Ren Y, Chen AM et al (2014) Peroxisome proliferator-activated receptor gamma ligands inhibit VEGF-mediated vasculogenic mimicry of prostate cancer through the AKT signaling pathway. Mol Med Rep 10, 276-282   DOI